Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C

Gastroenterology

Volumn 140, Issue 2, 2011, Pages 469-477

  Conjeevaram, Hari S ^a   Wahed, Abdus S ^b   Afdhal, Nezam ^c   Howell, Charles D ^d   Everhart, James E ^e   Hoofnagle, Jay H ^e  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Clinical Trial; Liver Disease; Metabolic Response; Obesity

Indexed keywords

GLUCOSE; INSULIN; PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; FEMALE; FIBROSIS; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HOMEOSTASIS; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; WEIGHT CHANGE;

EID: 79251554394     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2010.11.002     Document Type: Article

References (26)

1. G.L. Armstrong, A. Wasley, and E.P. Simard The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 Ann Intern Med 144 2006 705 714
2. M.G. Ghany, D.B. Strader, and D.L. Thomas Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
3. M.E. Allison, T. Wreghitt, and C.R. Palmer Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population J Hepatol 21 1994 1135 1139
4. A.L. Mason, J.Y.N. Lau, and N. Hoang Association of diabetes mellitus and chronic hepatitis C virus infection Hepatology 29 1999 328 333
5. C.O. Zein, C. Levy, and A. Basu Chronic hepatitis C and type II diabetes mellitus: a prospective cross-sectional study Am J Gastroenterol 1000 2005 48 55
6. M. Romero-Gomez Insulin resistance and hepatitis C World J Gastroenterol 12 2006 7075 7080
7. T. Kawaguchi, T. Yoshida, and M. Harada Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3 Am J Pathol 165 2004 1499 1508
8. M.Y. Sheikh, J. Choi, and I. Qadri Hepatitis C virus infection: molecular pathways to metabolic syndrome Hepatology 47 2008 2127 2133
9. L.E. Adinolfi, M. Gambardella, and A. Andreana Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity Hepatology 33 2001 1358 1364
10. L.F. Hourigan, G.A. Macdonald, and D. Purdie Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis Hepatology 29 1999 1215 1219
11. J.M. Hui, A. Sud, and G.C. Farrell Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression Gastroenterology 125 2003 1695 1704
12. I.H.Y. Chu, J.M. Hui, and J.G. Kench Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C Heaptology 48 2008 723 731
13. L. Fartoux, A. Poujol-Robert, and J. Guechot Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C Gut 54 2005 1003 1008
14. M. Romero-Gomez, M. Del Mar Viloria, and R.J. Andrade Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients Gastroenterology 128 2005 636 641
15. H.C. Conjeevaram, D.E. Kleiner, and J.E. Everhart Race, insulin resistance and hepatic steatosis in chronic hepatitis C Hepatology 45 2007 80 87
16. A.S.F. Lok, J.E. Everhart, R.T. Chung HALT-C Trial Group Hepatitis steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial Clin Gastroenterol Hepatol 5 2007 245 254
17. H.B. El-Serag, T. Tran, and J.E. Everhart Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma Gastroenterology 126 2004 460 468
18. H.S. Conjeevaram, M.W. Fried, and L.J. Jeffers Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 Gastroenterology 131 2005 470 477
19. D.R. Matthews, J.P. Hosker, and A.S. Rudenski Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 1985 412 419
20. J.C. Levy, D.R. Matthews, and M.P. Hermans Correct Homeostasis Model Assessment (HOMA) evaluation uses the computer program Diabetes Care 21 1998 2191 2192
21. A. Caumo, A. Brunani, and G. Perseghin New insights on the simultaneous assessment of insulin sensitivity and β-cell function with the HOMA2 method Diabetes Care 29 2006 2733 2734
22. K. Ishak, A. Baptista, and L. Bianchi Histological grading and staging of chronic hepatitis J Hepatol 22 1995 696 699
23. T. Kawaguchi, T. Ide, and E. Taniguchi Clearance of HCV improves insulin resistance, β-cell function, and hepatic expression of insulin receptor substrate 1 and 2 Am J Gastroenterol 102 2007 570 576
24. Y. Shintani, H. Fujie, and H. Miyoshi Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance Gastroenterology 126 2004 840 848
25. Y. Ito, N. Takeda, and M. Ishimori Effects of long-term interferon-α treatment on glucose tolerance in patients with chronic hepatitis C J Hepatol 31 1999 215 220
26. T.Y. Tai, J.Y. Lu, and C.L. Chen Interferon-α reduces insulin resistance and β-cell secretion in responders among patients with chronic hepatitis B and C J Endocrinol 178 2003 457 465